PF-Atlas › Clinical Trials › NCT04268485

Longitudinal Changes in Serum KL-6 in IPF

Serum KL-6 level · Not specified

Registry ID
NCT04268485
Phase
Not specified
Status
Unknown
Drug / intervention
Serum KL-6 level
Sponsor
Manchester University NHS Foundation Trust
Start
2021-02-01
Enrollment
60
Locations
1

About this trial

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis. More accurate tests to predict disease progression and response to treatment are required. Krebs von den Lungen-6 (KL-6) is a blood marker associated with IPF. Results from previous studies have shown that levels of KL-6 are higher in patients with IPF compared to people without the disease. In addition, it is not clear what impact treatment has on KL-6 levels, and whether this could help us to monitor how effective treatment for IPF is. The investigators plan to perform a study in which KL-6 levels in the blood of patients with a new diagnosis of IPF are measured at baseline, 3, 6 and 12 months to look for and changes in the levels of KL-6 in the blood.

View NCT04268485 on ClinicalTrials.gov →

Explore related

All Serum KL-6 level trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT04268485 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.